<DOC>
	<DOCNO>NCT00003664</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill kidney cancer cell . Interferon alfa may interfere growth cancer cell . Combining chemotherapy biological therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy biological therapy treat patient kidney cancer metastatic remove surgically .</brief_summary>
	<brief_title>Combination Chemotherapy Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic Can Be Removed Surgically</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect interferon alfa , interleukin-2 , gemcitabine , fluorouracil patient metastatic unresectable renal cell cancer . II . Evaluate feasibility possible therapeutic anticancer efficacy therapy patient . III . Determine duration response , survival , improvement quality life patient . OUTLINE : Patients receive fluorouracil IV day 1 , 8 , 15 , 22 , follow gemcitabine IV 30 minute day 29 , 36 , 43 , 50 . Interferon alfa administer subcutaneously 3 time weekly begin day 1 . Beginning day 2 , interleukin-2 administer subcutaneously 3 time weekly first 4 week treatment course . Treatment repeat every 8 week 4 course absence unacceptable toxic effect disease progression . Following chemobiotherapy , maintenance therapy administer patient stable respond disease . Patients receive subcutaneous interferon alfa 3 time weekly maximum tolerate dose disease progression maximum 1 year . A quality life assessment complete weekly . Patients follow death . PROJECTED ACCRUAL : A total 30 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic unresectable carcinoma kidney No CNS metastases PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 02 Life expectancy : Greater 4 month Hematopoietic : WBC least 3,500/mm3 Granulocyte count least 2,500/mm3 Platelet count least 100,000/mm3 PT great 1.3 time upper limit normal ( ULN ) Hematocrit least 28 % Hepatic : Bilirubin le 2.0 mg/dL SGOT great 1.25 time ULN ( unless due tumor ) Renal : Creatinine le 2.0 mg/dL Calcium le 12 mg/dL Proteinuria great 2.0 dipstick Cardiovascular : No active angina No uncontrolled congestive heart failure No uncontrolled arrhythmias No myocardial infarction within 6 month Pulmonary : No significant pulmonary disease ( RA pO2 less 60 pCO2 great 50 ) Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No active infection No daily emesis inability tolerate solid food No prior concurrent second malignancy within 2 year , except : Nonmelanoma skin cancer Carcinoma situ cervix No sever diarrhea ( great 4 watery stool per day ) No active pelvic inflammatory disease No inflammatory bowel disease No uncontrolled seizure disorder No personal family history malignant hyperthermia No recent thromboembolism condition require concurrent anticoagulation PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior gemcitabine No prior fluorouracil adjuvant fluorouracil receive least 1 year prior study No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid allow ( except nausea vomit ) Radiotherapy : At least 14 day since prior radiation axial skeleton No concurrent radiotherapy ( except local lesion ) Surgery : At least 14 day since prior exploration biopsy At least 21 day since prior resection anastomosis No major organ allograft Other : No concurrent barbiturates No concurrent oral anticoagulant No concurrent investigational drug device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>